Tocilizumab Therapy in Gram-Positive and Gram-Negative Pediatric Septic Shock: A Comparative Pilot Study

Area of Science:

• Pediatric critical care medicine
• Immunology
• Infectious diseases

Background:

• Elevated interleukin-6 (IL-6) correlates with increased severity and mortality in pediatric septic shock.
• This study examines tocilizumab, an IL-6 receptor antagonist, for treating pediatric septic shock caused by Gram-positive bacteria (GPB) and Gram-negative bacteria (GNB).

Purpose of the Study:

• To evaluate the efficacy of adjunctive tocilizumab in improving clinical outcomes for children experiencing septic shock.
• To assess the impact of tocilizumab on mortality rates, shock duration, and intensive care unit (ICU) length of stay, stratified by causative bacterial pathogen.

Main Methods:

• A retrospective cohort study involving 58 pediatric septic shock patients.
• Comparison between 32 patients receiving adjunctive tocilizumab and 26 historical controls.
• Outcomes analyzed included mortality, shock duration, and ICU length of stay, with subgroup analysis based on GPB and GNB infections.

Main Results:

• Tocilizumab treatment was linked to significantly shorter shock duration (median 84 vs. 240 hours) and reduced ICU stay (median 6 vs. 14 days).
• Mortality rates were substantially lower in the tocilizumab group (18.7% vs. 46.1%).
• Tocilizumab demonstrated significant benefit in Gram-negative bacteria (GNB) sepsis, reducing mortality (23.8% vs. 56.2%) and improving 28-day survival.

Conclusions:

• Adjunctive tocilizumab significantly improves survival and shortens shock duration in pediatric septic shock.
• Targeted IL-6 blockade with tocilizumab effectively mitigates hyperinflammation, particularly in severe Gram-negative bacterial infections.